Net Income

As cardiovascular disease affects nearly half of US adults, experts are urging a shift to existing, life-saving therapies that are widely ignored.

Verrica Pharmaceuticals heads to a key investor conference with strong YCANTH sales, a promising pipeline for warts and skin cancer, and high expectations.

With a novel skin drug launched, Pelthos Therapeutics heads to a key conference. Can its focused strategy convince Wall Street of its blockbuster potential?

ITF Therapeutics will unveil 10 new data presentations on its Duchenne therapy, DUVYZAT, offering critical new insights on long-term safety and efficacy.

With key investor conferences looming, Phathom Pharmaceuticals is set to showcase strong VOQUEZNA sales and a clear path to 2026 profitability.

After halting all R&D, PCI Biotech proposes dissolution and delisting, marking the end for its novel drug delivery platform and a warning for investors.

Pure Storage rebrands as Everpure and acquires 1touch, betting its future on providing the intelligent data management layer essential for enterprise AI.

The Biocodex Microbiota Foundation opens its 10th annual grant, committing a total of half a million dollars to shape the future of U.S. gut health science.

With its newly approved VIZZ eye drop, LENZ Therapeutics is wooing investors, aiming to capture a slice of the massive, underserved presbyopia market.

A new high-grade discovery deep beneath a century-old mine could revive a legendary BC mining district and bolster Canada's critical mineral supply.

With a soaring stock, $300M in new funding, and strong clinical data, Monte Rosa is set to showcase its novel disease-fighting drug platform.

Anavex Life Sciences adds AMEOS Group CEO Dr. Axel Paeger to its board, a strategic move signaling a push into European markets for its CNS therapies.

C4 Therapeutics begins a crucial study for its oral protein degrader, cemsidomide, offering new hope for heavily treated multiple myeloma patients.

With a key drug in trials and a pipeline nearing the clinic, Foghorn Therapeutics brings in a seasoned financial leader to navigate its path to market.

Montreal firm's advanced titanium powder will fuel next-gen aerospace innovation, highlighting its role in a critical, high-growth global market.

With revenue growth tied to shrinking margins, illumin's upcoming 2025 earnings report is a critical test of its strategy in a shifting ad tech world.

The biotech firm slashed a major acquisition hurdle in a deal with HealthCare Royalty, signaling strong confidence in its cancer drug ZYNLONTA's future.

Keurig's ubiquitous K-Cup pods are now recyclable in Ontario, marking a pivotal test for the province's new producer-funded waste system.

Armed with $320M in new capital, Anteris will showcase its revolutionary biomimetic heart valve to top investors. Can it disrupt a market of giants?

With key hires in exploration, finance, and permitting, Ambler Metals is accelerating its plan to unlock Alaska’s vast copper and cobalt resources.